Skip to content

Comparison of intravenous infusion of propofol and sodium valproate on alleviation of acute migraine

Comparison of intravenous infusion of propofol and sodium valproate on alleviation of acute migraine

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT2012121911822N1
Enrollment
60
Registered
2013-04-04
Start date
2013-04-04
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Migraine Headache. Migraine

Interventions

Intervention 1: ?A single dose of 200 mg propofol mixed with 500 ml normal saline within 45 minute. Intervention 2: A single dose 500 mg sodium valproate mixed with 500 ml normal saline within 45 minu
Treatment - Drugs
?A single dose of 200 mg propofol mixed with 500 ml normal saline within 45 minute.
A single dose 500 mg sodium valproate mixed with 500 ml normal saline within 45 minute.

Sponsors

Vice chancellor of Research and Technology, Hamadan University of Medical Science
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 50 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Acute migraine attack; 20 to 50 years; ASA=II Exclusion criteria: Patient refuse; Allergy to propofol or sodium valproate; Allergy to egg or soya

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Headache severity. Timepoint: Before administration of drugs and each 15 min during drug infusion and each 30 min for two hours. Also, in patient with reduced severity of pain we will assist pain severity for next 24 and 48 hours. Method of measurement: Numerical Rating Scale (NRS), 0 for without pain and 10 for worst pain.

Secondary

MeasureTime frame
Any side effect such as allergy. Timepoint: Each 15 min during drug infusion and each 30 min for two hours. Also, in patient with reduced pain for next 24 and 48 hours through the telephone. Method of measurement: Ask from patient according to Questionnaire.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactBehrooz Karkhanei

Hamadan University of Medical Sciences

karkhanei@umsha.ac.ir+98 81 1838 0574

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026